Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines

Prematurity Clinical Trial

Official title:
A Prospective, Randomized, Open-label Clinical Trial to Assess Apnea Following Administration of 13-valent Conjugate Pneumococcal Vaccine, Diphtheria Toxoid, Tetanus Toxoid, and Acellular Pertussis Vaccine, Inactivated Polio Vaccine, Hepatitis B Vaccine, and Haemophilus Influenzae Type B Vaccine in Preterm Infants

Status Completed

Clinical Trial Summary

A prospective, randomized open-label clinical trial will be conducted from July 2018 to October 2020. Approximately 300 preterm infants will be enrolled across three sites: Duke University Medical Center, the University of North Carolina, and Cincinnati Children's Hospital Medical Center. Eligible infants will be randomized 1:1 to receive either 2-month US licensed childhood vaccines (PCV13, DTaP, HBV, IPV an Hib) or no vaccines. After their participation in the study, healthcare providers of the infants in the unvaccinated group will make decision abut receipt of their 2-month childhood vaccines. The study will collect data from the continuous cardiorespiratory and pulse oximetry monitors from randomization to 48 hours after randomization for infants in the unvaccinated group, and from randomization to 48 hours after vaccination for infants in the vaccinated group. Infants in both groups will be monitored for up to 60 hours for the occurrence of apnea, bradycardia, and oxygen desaturation. For infants in the "vaccinated" group, the study will also collect adverse events of clinical interest and serious adverse events occurring between the end of the 48-hour monitoring period and 14 days after vaccination. This information will be collected through parental report and review of medical records.

Clinical Trial Description

Modified Intent-to-Treat (mITT) Analysis Population: Defined as any infant that was enrolled and randomized in the study For the mITT analysis, infants will be analyzed in their assigned treatment arms irrespective of receipt of vaccine. Study outcomes will be included in the analysis as follows: i) Vaccinated group: study outcomes in the 48-hour monitoring after vaccination. If vaccination does not occur by 12 hours after randomization, then study outcomes will be assessed between 12 and 60 hours after randomization. ii) Unvaccinated group: study outcomes in the 48-hour monitoring period after randomization. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03530124
Study type	Interventional
Source	Duke University
Contact
Status	Completed
Phase	Phase 4
Start date	July 17, 2018
Completion date	November 1, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03670732` - CPAP vs.Unsynchronized NIPPV at Equal Mean Airway Pressure	N/A
Completed	`NCT05322161` - Yoga in the NICU for Parents Study	N/A
Recruiting	`NCT04542096` - Real Time Evaluation of Dynamic Changes of the Lungs During Respiratory Support of VLBW Neonates Using EIT
Recruiting	`NCT04911452` - Creating a Calmer NICU: Optimizing Growth and Brain Development in Preterm Infants	N/A
Recruiting	`NCT02901652` - NIPPV and nBiPAP Methods in Preterm Infants With Respiratory Distress Syndrome	N/A
Completed	`NCT02148965` - Effects of Exercise During Pregnancy on Maternal and Child Health: a Randomized Clinical Trial	N/A
Completed	`NCT02273843` - A Trial on Different Dosages of Vitamin D in Preterm Infants With Late-onset Sepsis	Phase 1
Terminated	`NCT02032511` - Comparison of RAM Cannula Nasal Continuous Positive Airway Pressure Versus Infant Flow Nasal Continuous Positive Airway Pressure (NCPAP)	N/A
Completed	`NCT01721629` - Weaning of Nasal Continuous Positive Airway Pressure (CPAP) in Premature Infants	N/A
Terminated	`NCT01819532` - Milking the Umbilical Cord Versus Immediate Clamping in Pre-term Infants < 33 Weeks	N/A
Completed	`NCT01523769` - Umbilical Cord Milking on the Reduction of Red Blood Cell Transfusion Rates in Infants	N/A
Completed	`NCT01478711` - Comprehensive Clinical Decision Support (CDS) for the Primary Care of Premature Infants	N/A
Completed	`NCT00951860` - Assessment of Autonomic Maturation in Neonatal Period and Early Neural Development From a Longitudinal Prospective Cohort	N/A
Completed	`NCT00749008` - Study of Generalized Movements for Early Prediction of Cerebral Palsy	N/A
Completed	`NCT00787124` - Transfusions and Nitric Oxide Level in Preterm Infants
Terminated	`NCT01208493` - Dietary Protein in the Very-low-birth-weight Infant	N/A
Terminated	`NCT00486395` - Will CPAP Reduce Length Of Respiratory Support In Premature Infants?	Phase 3
Completed	`NCT00527956` - Facilitation and Barriers to Breastfeeding in the NICU	N/A
Completed	`NCT03372590` - NEO Rehab for Infants at Risk of Cerebral Palsy	N/A
Completed	`NCT00033917` - Indomethacin Germinal Matrix Hemorrhage/Intraventricular Hemorrhage (GMH/IVH) Prevention Trial	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.